Labiotech.eu

News and Trends 11 Aug 2022

Gemini Therapeutics and Disc Medicine announce merger agreement

Gemini Therapeutics and Disc Medicine have entered into a definitive merger agreement to combine in an all-stock transaction. The announcement came yesterday (August 10) and the combined company will focus on advancing Disc’s pipeline of hematology programs and is expected to operate under the name Disc Medicine Inc. upon shareholder approval. The work will include […]

August 11, 2022 - 2 minutesmins - By Liza Laws

News and Trends 11 Aug 2022

Synlogic gets Ginkgo Bioworks’ help to launch T. rex inspired synthetic biotic for gout

Synlogic, Inc. has announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks. The new candidate, SYNB2081, is a synthetic biotic and is the second product to advance to clinical development through a research collaboration between Synlogic and Ginkgo, following the investigational new drug candidate SYNB1353 for the potential […]

August 11, 2022 - 2 minutesmins - By Jim Cornall

beta-thalassemia blood APS antiphospholipid syndrome

News and Trends 11 Aug 2022

Study of drug to treat porphyria disorders initiated by Disc Medicine

A phase 2 clinical study of bitopertin in patients with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) has been initiated by Disc Medicine. The announcement of the study, called BEACON, was made August 10. EPP or XLP belong to a group of the porphyria disorders, which are all characterized by abnormally high levels of chemicals, […]

August 11, 2022 - 3 minutesmins - By Liza Laws

News and Trends 11 Aug 2022

Acquisition of TeneoTwo and its clinical-stage T-cell engager completed

AstraZeneca has said today (August 11) that it has completed its purchase of TeneoTwo including its B-cell non-Hodgkin lymphoma drug candidate. The company made an upfront payment of $100 million and then additional payments of up to $805 million contingent on research and development milestones as well as up to $360 million to TeneoTwo’s former […]

August 11, 2022 - 2 minutesmins - By Liza Laws

In Depth 11 Aug 2022

Biosecurity is synthetic biology’s most crucial ally

Synthetic biology has made it easier than ever to engineer organisms to serve our needs. But as the technology becomes widespread, concerns about its potential misuse arise. How can we ensure biosecurity without hindering the advance of synthetic biology? Biosecurity consists of the prevention of and response to the release of potentially harmful organisms. Now […]

August 11, 2022 - 6 minutesmins - By Kostas Vavitsas

News and Trends 10 Aug 2022

Aro Biotherapeutics gets FDA orphan drug designation for treatment of Pompe Disease

Aro Biotherapeutics says the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ABX1100, an investigational Centyrin-siRNA conjugate that targets the Gys1 gene in the muscle, for the treatment of Pompe disease. “We are pleased to have received this designation and are gratified by the FDA’s recognition of the potential of ABX1100 […]

August 10, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 10 Aug 2022

Stem cell therapy to be used in treatment of long COVID by Panacell Biotech

A South Korean biotech company says it will use natural killer (NK) cells, exosomes and brown adipose-derived stem cells (ADSC) as treatment of long COVID. NK cells are a type of immune cell that have granules or small particles that can kill tumor cells or those infected with a virus. Panacell Biotech said they can […]

August 10, 2022 - 3 minutesmins - By Liza Laws

News and Trends 10 Aug 2022

GentiBio and Bristol Myers Squibb to develop engineered Treg therapies for inflammatory bowel diseases

GentiBio, Inc. has entered into a collaboration with Bristol Myers Squibb to develop new engineered regulatory T cells (Treg) therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD). The collaboration brings together GentiBio’s engineered Treg platform for generating scalable, stable, highly-selective, and durable Tregs with Bristol Myers Squibb’s […]

August 10, 2022 - 2 minutesmins - By Jim Cornall

Interview 10 Aug 2022

How the UK precision breeding bill could unshackle gene editing

The U.K. is considering lowering restrictions on gene-edited crops. PacBio’s Neil Ward explains how the changes could impact the gene editing landscape. CRISPR gene editing technology has changed the game in the biotech industry by making it easier than ever before to make small changes to the genome. In addition to myriad healthcare applications, the […]

August 10, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 10 Aug 2022

Research discovery may help diagnose and treat cancer and brain disorders

Researchers at Queen’s University Belfast in Northern Ireland have revealed how the pathway of an identified protein could lead to early diagnosis and targeted treatment for several cancers and brain disorders. The team of researchers discovered how the journey or molecular pathway of an identified protein is both essential for brain development and how an […]

August 10, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 10 Aug 2022

Bone Therapeutics and Medsenic set to combine in share for share deal

Subject to the outcome of a shareholders’ meeting, Bone Therapeutics and Medsenic are set to combine their operations reducing risks and broadening portfolios. The companies announced they have signed a share for share binding contribution today (August 10) which will create new enterprise BioSenic. Brussels and Paris-based Bone Therapeutics is a cell therapy company that […]

August 10, 2022 - 3 minutesmins - By Liza Laws

News and Trends 10 Aug 2022

Captor Therapeutics names lead candidate in fight against hepatocellular carcinoma

A Polish biopharma company focused on treating cancer and autoimmune diseases announced today (August 10) that it has chosen a lead candidate for the treatment of hepatocellular carcinoma. The molecular glue candidate, CPT-6281 will be Captor Therapeutic’s CT-01 project which will initially focus on the clinical development of the asset as a targeted protein degradation […]

August 10, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Gemini Therapeutics and Disc Medicine announce merger agreement

Synlogic gets Ginkgo Bioworks’ help to launch T. rex inspired synthetic biotic for gout

Study of drug to treat porphyria disorders initiated by Disc Medicine

Acquisition of TeneoTwo and its clinical-stage T-cell engager completed

Biosecurity is synthetic biology’s most crucial ally

Aro Biotherapeutics gets FDA orphan drug designation for treatment of Pompe Disease

Stem cell therapy to be used in treatment of long COVID by Panacell Biotech

GentiBio and Bristol Myers Squibb to develop engineered Treg therapies for inflammatory bowel diseases

How the UK precision breeding bill could unshackle gene editing

Research discovery may help diagnose and treat cancer and brain disorders

Bone Therapeutics and Medsenic set to combine in share for share deal

Captor Therapeutics names lead candidate in fight against hepatocellular carcinoma

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!